In 2022, one third of the world’s medical spending will be it is said to be done in emerging countries.
Medical care is a field where the first-mover advantage can be fully demonstrated by acquiring a large amount of vital data. At first, we will strive to popularize prevention and medical care in emerging countries and collect vital data, and by letting machines learn the data, we will grow into an irreplaceable existence. And we deliver straight medical care to people in every corner of the world. This is an overwhelming advantage over developed countries with many regulations and vested interests. We collect a large amount of data and build a health care miup cycle such as health management, diagnostic assistance, and prevention with the aim of improving diagnostic assistance and risk prediction accuracy. We aim to create a wellness ecosystem that can utilize data for the next generation.
Get health information from mobile devices. By referring to all the accumulated data and personal log data, we can predict the risk of chronic diseases and support the interviews and diagnoses of distant doctors. Even when there are no symptoms, we provide personalized prevention and health advice. As this miup cycle evolves, AI will enable more accurate predictions and diagnoses. Also in medicine. By accumulating data on actions and side effects, we will be able to provide optimal medicines to individuals. Even from a macro perspective. We will make it possible to predict pandemics of infectious diseases and provide information to the national government, local governments, and companies. Furthermore, in developing countries where the insurance system is not in place, it will be possible to create medical insurance with less burden. miup will change medical care. This is because mobile devices have become widespread and technology has begun to bloom. Faster than anyone else. In a more rational way than anyone else. We will extend healthy life expectancy on the planet and increase the total amount of happy time.
Core Members
“Dr.Nakano brings over two decades of leadership experience from Japan’s most prestigious cancer institutions, including the National Cancer Center Tokyo and St.Luke’s International Hospital, where she served as Associate Director of the Oncology Center for 15 years. She began her medical career in both the United States and Japan, gaining a unique cross-cultural clinical perspective from the outset.
Her track record in clinical excellence, team management, and innovation in patient care has earned her a strong reputation in both public and private healthcare sectors.
With hands-on experience across international hospitals and a deep understanding of Japan’s world-class medical infrastructure, she joined Miup to scale Japanese healthcare innovation to global markets- bringing the highly efficient clinical standards with emerging healthcare needs worldwide.”
